Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis
- PMID: 25123086
- DOI: 10.1002/hep.27372
Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis
Abstract
Genetic determinants of the early steps of carcinogenesis on cirrhosis are still poorly understood. We aimed to evaluate the occurrence of telomerase reverse transcriptase (TERT) promoter mutations in the transformation of cirrhotic nodules into hepatocellular carcinoma (HCC). We analyzed a series of 268 liver samples, including 96 nodules developed in 58 patients with cirrhosis and 114 additional cirrhosis. All samples were screened for TERT promoter mutations, and in 31 nodules, for 10 genes recurrently mutated in HCC. Immunohistochemistry (IHC) analyses were performed for glypican 3, glutamine synthase, and heat shock protein 70. Six liver pathologists reviewed all the samples. Among The 96 nodules, 88 were firmly diagnosed as low-grade dysplastic nodules (LGDNs; 32 cases), high-grade dysplastic nodules (HGDNs; 16 cases), early HCC (eHCC; 23 cases), or small and progressed HCC in 17 cases. The agreement between the initial diagnosis from pathological report and the final expert consensus report was moderate for the diagnosis of benign versus malignant nodules (weighted kappa = 0.530). TERT promoter mutations were highly related to the step-wise hepatocarcinogenesis because mutations were identified in 6% of LGDNs, 19% of HGDNs, 61% of eHCCs, and 42% of small and progressed HCC. TERT promoter mutation is the most frequent molecular alteration in eHCC given that the IHC criteria for diagnosis of malignancy were found in only 39% of the cases. TERT promoter mutation was also the earliest genetic alteration because mutations in 10 other genes were only identified in 28% of the small and progressed HCC.
Conclusion: Frequency of TERT promoter mutations rapidly increases during the different steps of the transformation of premalignant lesions into HCC on cirrhosis. Consequently, somatic TERT promoter mutation is a new biomarker predictive of transformation of premalignant lesions into HCC.
© 2014 by the American Association for the Study of Liver Diseases.
Comment in
-
Reply.Hepatology. 2016 Jan;63(1):342. doi: 10.1002/hep.27827. Epub 2015 Jun 3. Hepatology. 2016. PMID: 25846279 No abstract available.
-
Telomerase reverse transcriptase promoter methylation is related to a risk of recurrence in hepatocellular carcinoma.Hepatology. 2016 Jan;63(1):341. doi: 10.1002/hep.27833. Epub 2015 Apr 30. Hepatology. 2016. PMID: 25847141 No abstract available.
Similar articles
-
Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations.World J Gastroenterol. 2015 Jan 7;21(1):311-7. doi: 10.3748/wjg.v21.i1.311. World J Gastroenterol. 2015. PMID: 25574106 Free PMC article.
-
TERT promoter mutations in primary liver tumors.Clin Res Hepatol Gastroenterol. 2016 Feb;40(1):9-14. doi: 10.1016/j.clinre.2015.07.006. Epub 2015 Aug 31. Clin Res Hepatol Gastroenterol. 2016. PMID: 26336998 Review.
-
Telomere shortening and telomerase reactivation in dysplastic nodules of human hepatocarcinogenesis.J Hepatol. 2003 Nov;39(5):786-92. doi: 10.1016/s0168-8278(03)00395-7. J Hepatol. 2003. PMID: 14568262
-
Telomerase activity in precancerous hepatic nodules.Cancer. 1998 May 15;82(10):1831-8. Cancer. 1998. PMID: 9587114 Clinical Trial.
-
Latest developments in precancerous lesions of hepatocellular carcinoma.World J Gastroenterol. 2016 Mar 28;22(12):3305-14. doi: 10.3748/wjg.v22.i12.3305. World J Gastroenterol. 2016. PMID: 27022212 Free PMC article. Review.
Cited by
-
Droplet-digital PCR reveals frequent mutations in TERT promoter region in breast fibroadenomas and phyllodes tumours, irrespective of the presence of MED12 mutations.Br J Cancer. 2021 Jan;124(2):466-473. doi: 10.1038/s41416-020-01109-8. Epub 2020 Oct 13. Br J Cancer. 2021. PMID: 33046803 Free PMC article.
-
Poly(U) binding splicing factor 60 promotes renal cell carcinoma growth by transcriptionally upregulating telomerase reverse transcriptase.Int J Biol Sci. 2020 Sep 25;16(15):3002-3017. doi: 10.7150/ijbs.45115. eCollection 2020. Int J Biol Sci. 2020. PMID: 33061812 Free PMC article.
-
Frequent somatic TERT promoter mutations and CTNNB1 mutations in hepatocellular carcinoma.Oncotarget. 2016 Oct 25;7(43):69267-69275. doi: 10.18632/oncotarget.12121. Oncotarget. 2016. PMID: 27661004 Free PMC article.
-
Reactivation of telomerase reverse transcriptase expression in cancer: the role of TERT promoter mutations.Front Cell Dev Biol. 2023 Nov 15;11:1286683. doi: 10.3389/fcell.2023.1286683. eCollection 2023. Front Cell Dev Biol. 2023. PMID: 38033865 Free PMC article. Review.
-
Mutation profile and its correlation with clinicopathology in Chinese hepatocellular carcinoma patients.Hepatobiliary Surg Nutr. 2021 Apr;10(2):172-179. doi: 10.21037/hbsn.2019.09.17. Hepatobiliary Surg Nutr. 2021. PMID: 33898558 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical